To focus the portfolio and unlock value, Smiths plans to divest Smiths Interconnect and Smiths Detection. Interconnect is slated for sale by the end of calendar 2025, while Detection will follow, ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical ...